ARS Pharma: Reimagining Epinephrine Administration for Allergic Reactions with Epinephrine Nasal Spray (neffy)

Monday, September 30
7:00 – 7:45 am
Location: Jasmine G

Speaker

James Augustine, MD, FACEP

Theater Information

This presentation explores the groundbreaking shift in anaphylaxis management through the use of neffy, the first needle-free epinephrine nasal spray approved for emergency treatment of severe allergic reactions. Traditionally, epinephrine has been administered via auto-injectors, posing barriers such as needle anxiety, incorrect use, and low adherence among patients. Neffy offers an innovative alternative, designed to simplify epinephrine administration while maintaining efficacy comparable to injectable forms. The presentation will delve into the clinical data supporting neffy’s approval, highlighting its pharmacokinetics, safety, and efficacy profiles. Attendees will gain insights into how this novel delivery method could address challenges in anaphylaxis treatment, particularly for individuals hesitant to use injectable devices. Key findings from comparative studies and real-world patient scenarios will be discussed, illustrating the potential for increased patient acceptance and improved emergency care outcomes. By reimagining epinephrine administration with neffy, healthcare providers can expand options for patients at risk of life-threatening allergic reactions, ensuring they are better equipped to manage anaphylaxis confidently and effectively. This session is essential for allergists, emergency responders, and other healthcare professionals looking to stay informed about the latest advancements in anaphylaxis management.

Supported by ARS Pharma